Evaluating adverse cardiovascular effects of drug treatment for benign prostatic hyperplasia (BPH) Methodological considerations

« Previous Next »Journal of Clinical Epidemiology
Volume 54, Issue 5 , Pages 518-524, May 2001

Evaluating adverse cardiovascular effects of drug treatment for benign prostatic hyperplasia (BPH)

P.C Souverein
- Department of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences (UIPS), PO Box 80082, 3508 TB Utrecht, The Netherlands
- Corresponding author. Tel.: +31-30-253 7324; fax: +31-30-253 9166.(P.C. Souverein)
R.M.C Herings
- Department of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences (UIPS), PO Box 80082, 3508 TB Utrecht, The Netherlands
J.J.M.C.H De la Rosette
- Department of Urology, University Hospital Nijmegen, PO Box 9101, 6500 HB Nijmegen, The Netherlands
A.J.Man in ‘t Veld
- Department of Internal Medicine, University Hospital Dijkzigt, PO Box 1738, 3000 DR Rotterdam, The Netherlands
R.D.T Farmer
- European Institute of Health and Medical Sciences, University of Surrey, Stirling House, Stirling Road, Guildford, Surrey 942 SRF, UK
H.G.M Leufkens
- Department of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences (UIPS), PO Box 80082, 3508 TB Utrecht, The Netherlands